Connetics Olux "approvable"
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Connetics' topical corticosteroid foam Olux (clobetasol propionate, 0.05%) is "approvable" Oct. 24 for the treatment of non-scalp psoriasis. Connetics expects approval of the sNDA by year-end. Olux is currently indicated for steroid-responsive scalp dermatose